RespireRx Pharmaceuticals Inc. to Present at 2017 Rodman & Renshaw Conference

GLEN ROCK, NJ--(Marketwired - Sep 8, 2017) - RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) ("RespireRx" or the "Company"), a leader in the development of medicines for the treatment of respiratory disorders, including sleep apnea, opioid-induced respiratory depression, and respiratory insufficiency due to spinal cord injury, announces that the Company's Chief Executive Officer and Vice Chairman of the Board of Directors, James S. Manuso, Ph.D., will present at the 2017 Rodman & Renshaw Conference on Tuesday, September 12, 2017 at 1:45 PM Eastern Time The presentations will be held at the Palace Hotel in New York, September 11-12, 2017.

Dr. Manuso will discuss RespireRx's successfully completed Phase IIB clinical trial of dronabinol in the treatment of obstructive sleep apnea, and will present the results of a Phase IIA trial evaluating the ability of CX-1739 (oral) to antagonize the drug-induced respiratory depression produced by the powerful opioid, remifentanil. He will also provide updated information and clinical development plans for the company's pipeline products.

Dr. Manuso's presentation will be available by live webcast streaming online and will be archived. To access the live audio webcast, go to http://wsw.com/webcast/rrshq27/rspi. A copy of the slide presentation to be presented at the conference will be submitted to the Securities and Exchange Commission in a Current Report on Form 8-K prior to the presentation and will also be available in the investors section of the RespireRx website.

About RespireRx Pharmaceuticals Inc.
RespireRx Pharmaceuticals Inc. is a leader in the development of medicines for respiratory disorders, with a focus on sleep apneas and drug-induced respiratory depression. The Company has licensed and owns patents and patent applications, and holds exclusive licenses, for certain use patents for the use of ampakines for the treatment of disordered breathing. During the first quarter of 2018, the Company plans to meet with FDA to discuss its Phase III clinical trial program to test the safety and efficacy of dronabinol for the treatment of obstructive sleep apnea.